Gland Pharma

    GLAND
    Pharma
    ₹3,230.50
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹53,308 Cr

    P/E
    43.10
    Day range
    ₹3,208.70 – ₹3,278.00
    52-week range
    ₹1,573.60 – ₹3,429.00
    Volume
    2.46 L
    Open
    ₹3,260.00
    Prev close
    ₹3,248.40

    Latest results · Q2 FY27(consolidated)Revenue ₹1,834 Cr+23.3%Profit ₹291 Cr+58.3%Margin 15.9%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter holding falling

      45.75%, down 6.08 pts since 2025-09-30 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 70 / 100

    Factor percentiles

    Value41
    Quality66
    Momentum91
    Low volatility82

    Derived metrics

    Earn. yield
    2.3%
    Graham no.
    ₹1,035.81
    vs Graham
    -67.9%
    ROE ÷ P/B
    2.0%
    12-1 mom.
    +61.8%
    Return / vol
    2.22
    Magic Formula
    #439
    Piotroski
    6/6
    FCF yield
    1.0%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Gland PharmaGLAND₹53,308 Cr43.105.1510.5%15.0%26.0%0.02+23.3%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 4d ago

    Headlines about Gland Pharma from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    42.6
    Price / Book
    4.99
    ROE (FY26)
    10.5%
    ROCE (latest year)
    15%
    Dividend yield
    0.62%

    Moving averages (NSE)

    20-day
    ₹3,120.44
    Price above
    50-day
    ₹3,031.27
    Price above
    200-day
    ₹2,365.51
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +21.1%
    Profit 3Y CAGR
    +9.6%
    Revenue YoY (Sep 2026)
    +23.3%
    Profit YoY (Sep 2026)
    +58.2%
    Operating margin
    26.0%
    Net margin
    15.9%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • Public
    • FII
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2018 (S)Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr5K Cr10K Cr15K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2019 (S)Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY25FY26FY27₹0₹5₹10₹15₹20

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales1,5451,5371,4021,4061,3841,4251,5061,4871,6951,7431,8001,834
    YoY Sales growth————-10-7——————
    Expenses1,1891,1791,1371,1091,0241,0771,1381,1731,2601,2301,3111,350
    Operating Profit356359264297360348368314435513489484
    OPM %23%23%19%21%26%24%24%21%26%29%27%26%
    Other Income3742516058445884391116169
    Interest5106623712841047
    Depreciation1059392949696101106108109111115
    Profit before tax283298218257299288313284362506435431
    Tax %32%35%34%36%32%35%31%35%28%28%27%33%
    Net Profit192192144164205187215184261367317291
    EPS in Rs₹11.65₹11.68₹8.73₹9.93₹12.42₹11.32₹13.08₹11.15₹15.87₹22.26₹19.21₹17.62

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days107

    +36 days since Mar 2021

    Inventory Days284

    -28 days since Mar 2021

    Days Payable136

    +39 days since Mar 2021

    Cash Conversion Cycle255

    -31 days since Mar 2021

    Working Capital Days145

    -24 days since Mar 2021

    Strengths, risks & growth

    Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

    Strengths

    • Company is almost debt free.
    • Company has been maintaining a healthy dividend payout of 39.1%

    Risks

    • Stock is trading at 4.99 times its book value
    • Promoter holding has decreased over last quarter: -6.02%
    • Company has a low return on equity of 9.29% over last 3 years.

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +13%
    3 Years
    +21%
    TTM
    +22%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +1%
    3 Years
    +8%
    TTM
    +59%

    Stock Price CAGR

    10 Years
    —
    5 Years
    -1%
    3 Years
    +26%
    1 Year
    +83%

    Return on Equity

    10 Years
    —
    5 Years
    +11%
    3 Years
    +9%
    Last Year
    +11%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter51.83%51.83%51.77%45.75%-6.02 pp
    FII7.58%7.29%8.74%10.36%+1.62 pp
    DII32.99%33.36%30.44%33.21%+2.77 pp
    Government0.00%0.00%0.00%0.01%+0.01 pp
    Public7.62%7.52%9.06%10.68%+1.62 pp

    Filed with NSE for Sept 2026: promoters 45.75%, public 54.25%

    Analysts & fund holdings

    77%
    77% recommend buy
    13 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E43.1 vs 45.2
    Sector P/B6.05
    Beta0.25

    Who holds the shares, quarter by quarter

    Mutual funds 29.52% (+1.29 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters45.8%
    • Foreign institutions10.4%
    • Mutual funds29.5%
    • Insurance2.4%
    • Other domestic institutions1.3%
    • Retail4.0%
    • Others6.7%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Mid Cap Fund3.36%1.87%+0.42 pp
    Kotak Mid Cap Fund2.59%2.24%+2.23 pp
    SBI Large & Midcap Fund1.79%2.47%+0.60 pp
    Nippon India Growth Mid Cap Fund1.59%1.77%+0.39 pp
    Nippon India Small Cap Fund1.01%0.74%+0.16 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    32.3%
    Downside volatility
    24.4%
    Worst 5% of days
    2.7%
    Average of that tail
    3.4%
    Max drawdown (1Y)
    21.1%
    Below its peak
    4.6%

    Against the market

    Beta vs Nifty 50
    0.53
    Correlation
    0.22
    Relative strength (3M)
    +7.1%
    ATR (14)
    3.2%

    Return

    Return 1M
    +6.1%
    Return 3M
    +11.0%
    Return 6M
    +49.8%
    Return 1Y
    +71.7%
    vs 200-day average
    +36.6%

    Momentum

    RSI (14)
    57.3
    MACD histogram
    10.15
    Stochastic %K
    52.5
    ADX (14)
    33.4
    +DI / −DI
    26.4 / 15.3
    Money flow index
    83.1

    Participation

    Delivery (20d avg)
    55.7%
    vs its 60-day baseline
    +1.4 pts
    Volume vs 20-day
    -0.5σ
    Close vs day's VWAP
    -0.2%
    52-week position
    91 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    6 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹537 Cr
    FCF yield
    1.0%
    Cash conversion
    1.00
    Accruals ratio
    -0.000
    Net debt
    -₹3,190 Cr
    Net debt / equity
    -0.30
    EV / sales
    7.09
    Capex intensity
    7.7%
    Revenue CAGR
    18.3%
    Profit CAGR
    34.4%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹28.1 L
    0 buys · ₹0
    4 sells · ₹28.1 L
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    A. JAYATHEERTHA
    Employees/Designated Employees · Market Sale
    Sell100₹1.9 L11 Feb 2026
    A. JAYATHEERTHA
    Employees/Designated Employees · Market Sale
    Sell306₹5.9 L5 Feb 2026
    P LAKSHMI NARAYANA
    Employees/Designated Employees · Market Sale
    Sell800₹14.9 L5 Feb 2026
    P LAKSHMI NARAYANA
    Employees/Designated Employees · Market Sale
    Sell300₹5.4 L25 Nov 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹20.00

      Dividend - Rs 20 Per Sh

      11 Aug 2026
      ex-date
    • dividend
      ₹18.00

      Dividend - Rs 18 Per Share

      14 Aug 2025
      ex-date
    • dividend
      ₹20.00

      Annual General Meeting/Dividend - Rs 20 Per Share

      16 Aug 2024
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      6 Aug 2021
      ex-date

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Reg 74(5) of the SEBI (DP) Regulations, 2018

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication regarding the dipatch of Notice of Postal Ballot

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    Postal Ballot Notice

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Directorate

    Resignation of Mr. Wenjie Zhang as a Non-Executive & Non-Independent Director and Appointment of Mr. Xingli Wang as an Additional Director (Non-Executive and Non-Independent Director)

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Updates on Acquisition

    Investment by Gland Pharma Limited in Gland Pharma USA Inc. and Investment by Gland Pharma USA Inc. into Novelstar Pharma Inc.

    Others
    Board Meeting Outcome for Outcome Of Board Meeting - 01-10-2026

    Outcome of Board Meeting held on October 01, 2026

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Fosun Pharma Industrial Pte Ltd

    Insider Trading / SAST
    Closure of Trading Window
    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Copy of Newspaper Publication

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Acquisition

    Acquisition of Gland Pharma USA Inc., a wholly-owned Step down subsidiary from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company

    Others
    Board Meeting Outcome for Outcome Of Board Meeting

    Outcome of Board Meeting

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of 44,193 Equity Shares on exercise of ESOPs

    Company Update
    Grant Of Stock Options Under Gland Pharma Employee Stock Option Scheme, 2025

    Grant of Stock Options under Gland Pharma Employee Stock Option Scheme, 2025

    Company Update
    Board Comments On Fines Levied By Exchanges

    Board Comments on fines levied by Exchanges

    Filed with BSE (scrip 543245); the last 45 days. Documents open at bseindia.com.

    Documents

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 7 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Gland Pharma: common questions

    Answered from the figures on this page.

    Gland Pharma last traded at ₹3,230.50 (NSE, as of 18 Nov 2026). The last session moved it down 0.55%.

    Gland Pharma is valued at about ₹53,308 crore (NSE, as of 18 Nov 2026).

    Gland Pharma trades at a price-to-earnings ratio of 43.10 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Gland Pharma has traded between ₹1,573.60 and ₹3,429.00 over the past 52 weeks, to 18 Nov 2026. It is currently 89% of the way up that range.

    Gland Pharma (GLAND) is classified under Pharma on this site's screener.